Trial
NCT00604461
Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Genentech, Inc.
Condition
Mesothelioma
Intervention
Carboplatin, Bevacizumab and Pemetrexed
Why stopped
Slow Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-23